Low Adherence to Tamoxifen Therapy Increases Risk of Breast Cancer Recurrence and Early DeathJo Cavallo
Tamoxifen increases risk for endometrial cancer (risk ratio, 2.13 [CI, 1.36 to 3.32]; 3 trials) compared with placebo by 4 per 1000 women per year ... Nelson,D Heidi,R Fu,... - 《Annals of Internal Medicine》 被引量: 133发表: 2009年 Levonorgestrel intrauterine system for endometrial pr...
However, studies have suggested that incidence and severity of endometrial ca... Bernard,Fisher,Joseph,... - 《Jnci J Natl Cancer Inst》 被引量: 2345发表: 1994年 Risk of endometrial cancer after tamoxifen treatment of breast cancer. Supports the hypothesis that the use of tamoxifen increases ...
Exposure to endoxifen (major active metabolite of tamoxifen) is strongly associated with CYP2D6 metabolizer phenotype, and low endoxifen concentrations are associated with increased risk for disease recurrence in women receiving adjuvant tamoxifen therapy for breast cancer; however, the validity of CYP2D6...
In the anastrozole adjuvant trial, coadministration of anastrozole and tamoxifen in breast cancer patients reduced anastrozole plasma concentration by 27% compared to those achieved with anastrozole alone; however, the coadministration did not affect the pharmacokinetics of tamoxifen or N-desmethyltamoxifen...
Although tamoxifen reduces the risk of breast cancer recurrence, and may have beneficial effects on serum lipids and the cardiovascular system, tamoxifen increases the risk of endometrial cancer, stroke and pulmonary emboli, so its use requires careful assessment of the potential benefits and risks.[...
Tamoxifen has been shown to increase cytoplasmic free Ca2+ levels (Ca2+)i in renal tubular cells and bladder cancer cells, and to alter Ca2+ signaling in MCF-7 breast cancer cells. The present study examined the effect of tamoxifen on (Ca2+)i in ZR-75-1 human breast cancer cells using...
What Is Nolvadex? Nolvadex (tamoxifencitrate) is a nonsteroidalantiestrogenused to treatbreast cancerthat has spread to other parts of the body (metastatic breast cancer), to treat breast cancer in certain patients after surgery andradiation therapy, and to reduce the chances of breast cancer in...
Prolonged tamoxifen treatment increases relapse-free survival for patients with primary breast cancer expressing high levels of VEGF: Sanchez BC, Sundqvist M, Fohlin H, et al (Karolinska Inst and Univ Hosp, Stockholm, Sweden; Kalmar Hosp, Sweden; Univ Hosp, Linköping, Sweden; et al) Eur ...
breast cancercalled ductal carcinomain situ(DCIS or intraductal carcinoma). Women who have had DCIS are at high risk for developing invasive breast cancer at a later date, and tamoxifen prevents development of the invasive cancer in almost half of the women during the first five years of ...